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Site.-directed mutagenesis was used to generate mutants of mouse dihydrofolate reductase more resistant o methotrexate than the wild type enzyme. 
The mutant genes were used to transfect either DHFR- or DHFR+ cell lines. These. mutants, as well as the wild type gene, were able to confer 
methotrexate resistance to DHFR- CHO cells. The number of selected colonies decreased with increased concentrations of methotrexate. The 
number of colonies observed at 10 PM methotrexate is correlated with the K,(MTX) of the enzyme: the higher the 4, the higher the number of 
colonies for the corresponding mutant. In contrast, the transfections of DHFR+ cells gave a few numbers of colonies not different for the wild 
type and the mutants. 
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1. INTRODUCTION 
Several dominant selective markers have been 
adapted for use in gene-transfer experiments [l]. Of 
particular interest for in vivo gene transfer is the gene 
coding for dihydrofolate reductase (DHFR; 5,6,7,8-te- 
trahydrofolate: NADP + oxidoreductase, EC 1 S. 1.3). 
The folate analogue methotrexate (MTX) binds tightly 
to the catalytic site of the wild-type enzyme, resulting in 
a complete loss of DHFR activity at very row concentra- 
tions of MTX and thus, death of the cell. Obtention of 
a cDNA encoding an altered DHFR with an increased 
resistance to MTX might provide a dominant, 
metabolically selectable marker that could facilitate the 
introduction of foreign genes into a wide variety of 
mammalian cells. This marker has also an advantage in 
that it can be amplified [2], and amplification may be 
associated with increases in both copy number and ex- 
pression of cotransferred genes [3]. 
Several mutant forms of DHFR have been identified 
in cultured cells that survive high doses of MTX [4-61. 
We used site-directed mutagenesis to produce mutants 
of mouse DHFR more resistant o MTX than the wild- 
type enzyme [7]. We obtained a wide range of mutants 
with Ki’s increased from 102 to 7.5 x lo’-fold com- 
pared to that of the wild-type enzyme (0.004 nM). The 
two mutants exhibiting the highest Ki (MTX) and two 
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other mutants obtained by in vivo selection in B. subtilis 
181 were used to transfect mammalian cells with 
DHFR - or DHFR + phenotypes. A correlation could 
be established between the modified properties of the 
various mutants and their capacity to make the recom- 
binant cells resistant o methotrexate. 
2. MATERIALS AND METHODS 
Obtention of the mutants by site-directed mutagenesis, purification 
of the proteins and kinetic assays were performed as previously 
described [7]. 
2.1. Transfection of eucaryotic ells 
DHFR- Chinese hamster ovary (CHO) DXBll [9], mouse L [lo], 
and mouse teratocarcinoma PCC4 [ll] cells were grown in Dulbec- 
co’s modified Eagle’s medium supplemented with 8% fetal calf 
serum. Since they are DHFR - and Pro-, for growing DXBll cells 
the medium was supplemented with hypoxanthine. glycine, thymldine 
(HGT) and proline 191. For transfection, 24 h after seeding 3 x ld 
cells into 60 mm diameter tissue culture dishes, a calcium precipitate 
prepared with 5 pg of undigested plasmid DNA was added to the 
culture medium, and left 48 h [12]. The cells were then washed. 
dispersed, counted and plated in growth medium at ld cells (for 
PCC4) or at ld cells (for DXBll and L) per 100 mm dish. After 24 
h growth medium was replaced by selective medium, i.e. Dulbecco’s 
medium lacking HGT for DXBl 1 cells in the absence or presence of 
methotrexate, or Dulbecco’s medium for L and PCC4 cells sup- 
plemented with the desired concentration of methotrexate. 
3. RESULTS AND DISCUSSION 
3.1. Inhibition of dihydrofolate reductase by metho- 
trexate 
Table I lists the positions of the mutations obtained 
in mouse DHFR either by selection in bacteria in 
presence of methotrexate (Phe-31 -> Ser and Gln-35 
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Table I 
Kinetic parameters of dihydrofolate reduction 
Ki (MTX) &(HzF) VU% 
(nM) @M) (min - ‘) 
DHFR+ 0.004 f 0.001 0.09 f 0.02 360 f 30 
Phe+Ser 31 4.4 f 1 4.5 f 0.5 330 f 30 
Gln+Pro 35 175 f 10 20 *2 n.d.’ 
Phe-tArg 31 190 f 10 2.5 f 0.5 60 f 10 
Leu+Arg 22 3000 f 100 1 f 0.2 6rtl 
‘Not determined 
- > Pro) [8] or by site-directed mutagenesis (Phe-3 1 - > 
Arg and Leu-22 - > Arg) [7]. The inhibition constants 
(Ki) for methotrexate of the different enzymes as well as 
their kinetic parameters versus dihydrofolate, the 
substrate competing with methotrexate for the same 
binding site, are also listed in Table I. The Km (HsF) is 
increased for all mutants but to a lesser extent than the 
Ki for methotrexate. The Vmax is decreased for Arg-31 
and Arg-22 mutants which indicates a decreased effi- 
ciency of transformation of substrate to product. One 
constant which combines mutational effects on Km’s 
and Ki’S is the ISO, the concentration of methotrexate 
which inhibits the reduction of dihydrofolate by 50%. 
Fig. 1 shows the inhibition curves which give the ISO, us- 
ing crude extracts under defined experimental condi- 
tions (see legend). Under these conditions, the 150 is 
3 x lo- 9 M for the wild type enzyme and respectively 
5x lo-* M, 4x lo-’ M, 9x lo-’ M and 3x lo-’ M 
for Ser-3 1, Pro-35, Arg-3 1 and Arg-22 mutants. Arg-22 
mutant exhibits the highest Ki and ISO. K, for 
dihydrofolate of this mutant is not very much changed 
indicating an efficient binding but the Vmax is 
dramatically decreased indicating a lowered activity. 
3.2. Construction of eucaryotic vectors 
The different DHFR cDNAs were cloned in the pSV2 
eucaryotic expression vector as described in Fig. 2, to 
generate the respective pSVZDHFR mutant plasmids 
as well as the pSV2-DHFR+ used as a control. A uni- 
que Fnu4Hl site located 7 bases before the ATG of 
DHFR cDNA was used to join the coding sequence of 
DHFR to the early promoter of SV40. pSV2 vectors 
carrying various selective markers have been shown to 
be very efficient for transfection of numerous cell lines. 
3.3. Transfection of cells with the recombinant 
plasmids 
The kinetic parameters of the various mutants clearly 
indicated that they had presented different decreases 
for the binding of methotrexate (Fig. 1). It was in- 
teresting to test if the differences were correlated to the 
ability of the various mutants to confer a methotrexate 
resistance to eucaryotic cells. For that purpose, CHO 
DHFR- cells were transfected with either the wild-type 
or the mutant plasmid constructions and colonies were 
selected in the absence of HGT. Various concentrations 
of methotrexate were added to the selective medium at 
the initial time of the selection. Colonies were stained 
and counted two weeks after the selective medium had 
been applied and the results are shown in Table II. In 
the absence of methotrexate, the number of colonies is 
not identical from one plasmid to the other. This result 
can be attributed to the thermal stability of the mutant 
proteins. We have previously demonstrated [7] that the 
[METHOTREXATE] 
Fig. 1. Measurement of 150 on crude extracts. DHFR was assayed spectrophotometrically as follows: 100 PM NADPH, 100 mM potassium 
phosphate, pH 7.9, 100 mM potassium chloride, in a total volume of 1 ml. Incubation time in presence of methotrexate was 10 min at 25°C and 
the reaction was initiated by addition of 50 gM HzF. Percent inhibition was calculated from an assay without methotrexate. 1, Wild-type; 2, Ser-3 1; 
3, Pro-35; 4, Arg-31; 5, Arg-22. 
451 
Volume 269, number 2 FEBSLETTERS September 1990 
FnulHl Bglll Bglll 
I 
X Fnu4Hl 
x Bglll 
lsola14 600 bp fragment 
a pSVP-globin Hand Ill BamHl 
X Hind III 
X EamHl 
Isolate wctor 
sticky end ligation (Bglll!BamHl) 
J 
Ftll in wth Klenow 
Blunt end ligation 
Fig. Z.Construction of DHFR eucaryotic expression plasmids. Dark 
dahsed lines, pSV2 vector; dark lines, pUC8 sequences; dashed lines, 
DHFR sequences. 
Pro-35 protein was less stable while Arg-3 1 and Arg-22 
were more stable than the wild type enzyme at 37°C. 
Ser-31 has the same stability as the wild type enzyme. 
The low efficiency of Pro-35 can be due to a lower 
amount of protein present in the cell after the transfec- 
tion and vice-versa for Arg-31 and Arg-22. 
In the presence of methotrexate, colonies obtained 
after transformation by pSV2-DHFR mutants were 
able to propagate in much higher levels of methotrexate 
than colonies derived from transfections with 
pSVZDHFR + , with the exception of Pro-35 for the 
reasons mentioned above. Moreover, the number of 
colonies obtained increased according to the Ki (MTX) 
for each mutant: the higher the Ki, the higher the 
number of colonies. 
1 PM methotrexate is largely above the concentration 
which is toxic for wild-type mammalian cells. At that 
methotrexate concentration, the pSVZDHFR + 
plasmid still gave rise to a large number of colonies. 
This apparent discrepancy might be explained by the 
presence of a larger amount of DHFR in the transfected 
cells than in a wild-type DHFR + cell. Such a hypothesis 
is difficult to check by direct assay of DHFR activity in 
cellular extracts since the activity is almost undetectable 
by spectrophotometric assay in wild type cells: 1.25 + 
0.25 pm01 THF/min per mg (units) compared to the 
Table II 
Transfection efficiencies of the different pSV2-DHFR plasmids in 
DHFR- CHO cells 
lMTx1 DHFR + ser-31 Pro-35 Arg-31 Arg-22 
0 37O~t30 29Of30 1OOrt20 >lOOO 71000 
100 nm 165 rt 20 142 f 20 50 f 10 >lOOO 71mo 
1 FM 26 f 10 107 f 20 20 z+ 15 250 f 30 350 f 30 
10 IrM 0 lOf5 0 60 f 10 280 f 30 
background: 1 f 0.2 units. However, the activity of 
transfected cells is slightly above the background in (2.7 
+ 0.3 units), possibly because the number of integrated 
copies is high in transfected cells (data not shown). 
Since the mutant plasmids were able to convert 
DHFR - to DHFR + cells capable of growing at 
methotrexate concentrations ufficient to suppress the 
endogeneous enzyme activity of wild-type cells, we ex- 
plored the use of the mutant cDNAs as dominant selec- 
tive markers in cells producing normal levels of 
unaltered DHFR, The concentration of methotrexate 
necessary to kill non transfected cells is 200 nM for L 
cells and 50 nM for PCC4. Transfection experiments 
were performed under the same conditions as for 
DHFR - CHO cells but using 300 nM MTX for L cells 
and 80 nM for PCC4 cells. In 10 different experiments, 
the frequency of colonies obtained with mutant 
plasmids was very low compared to the frequency ob- 
tained with DHFR- CHO as well as to the frequency 
obtained in control experiments with another selective 
marker such as pSV2-gpt. Moreover, most of the col- 
onies did not survive after transfer. These results were 
different from those obtained by Simonsen and Levin- 
son [13]. We have tried to reproduce exactly their ex- 
periments, i.e. applying the selective medium after 48 h 
(instead of 24 h), staining the colonies after 10 days (in- 
stead of two weeks), and using the pFR400 plasmid 
(containing the Arg-22 mutant cDNA as in our case but 
with a different 3’ end regulatory region). These 
modifications did not improve the results. A higher 
number of colonies was detected by staining at day 10 
but they were not viable after transfer. 
We can interpret the different results obtained with 
DHFR - CHO and DHFR+ cell lines as follows: in case 
of DHFR+ cells, if the catalytic activity or the Km for 
dihydrofolate is too much modified, as it was the case 
for all the mutants examined, there is no selective ad- 
vantage given by the transfected cDNA versus the wild- 
type enzyme already present in the cell. If the actrivity 
of the endogenous enzyme is limited by the availability 
of the substrate concentration, a variant enzyme 
capable of binding substrate but with a very low effi- 
ciency of conversion to product, could be considered as 
an inhibitor of the endogenous DHFR enzyme. In that 
case, even if the affinity of the mutant for MTX is 
greatly decreased, this is not a selective advantage. This 
conclusion was also reached by Gordon 1141 who con- 
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strutted transgenic mice with the Arg-22 mutant. The 
mice exhibited developmental anomalies identical to 
those observed upon administration of thymidylate syn- 
thetase inhibitors to fetal rats. This enzyme produces 
dihydrofolate and thus, its inhibition leads to a decrease 
of intracellular pool of this compound [15]. 
4. CONCLUSION 
Wild-type mouse dihydrofolate reductase cDNA has 
been proven to be very efficient to transfect DHFR- 
cells and to co-amplify an associated gene [3]. Mutants 
of mouse DHFR can also transfect these cells, 
sometimes with a higher efficiency than the wild type 
DHFR (Table II). However, the selective advantage of 
an increased resistance to MTX is not real when wild 
type cells are used in which they rather behave as simple 
competitive inhibitors of the endogeneous enzyme. 
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